ストックスクリーナーアプリを入手
20.46
2.27%
-0.47
前日終値:
$20.93
開ける：
$20.82
24時間の取引高:
1.15M
Relative Volume:
0.75
時価総額：
$3.19B
収益：
$340.81M
当期純損益:
$-419.65M
株価収益率:
-7.1789
EPS:
-2.85
ネットキャッシュフロー:
$-402.10M
1週間 パフォーマンス:
+13.70%
1か月 パフォーマンス:
+21.68%
6か月 パフォーマンス:
+41.36%
1年 パフォーマンス:
-12.13%
1日の値動き範囲:
$20.38
$21.39
1週間の範囲:
$17.18
$21.39
52週間の値動き範囲:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
20.45 | 3.27B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.40 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.13 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.55 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.91 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.33 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3%Here's Why - MarketBeat
Shorts Report: What are analysts price targets for Denali Therapeutics IncExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
3 Biotech Stocks That Could Double In 2026 - AOL.com
Stock Market Recap: What are analysts price targets for Denali Therapeutics IncJuly 2025 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Liquidity Mapping Around (DNLI) Price Events - Stock Traders Daily
Aug Big Picture: Can Denali Therapeutics Inc withstand a market correctionRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Aug Breakouts: Whats the outlook for Denali Therapeutics Incs sectorPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Chart Watch: Whats the outlook for Denali Therapeutics Incs sectorAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 40% Undervalued - 富途资讯
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Aug Patterns: Can Denali Therapeutics Inc withstand a market correctionMarket Performance Recap & Weekly High Conviction Trade Ideas - baoquankhu1.vn
FOMO Trade: What makes FTRE stock attractive todayInflation Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com
Earnings Recap: Is BranchOut Food Inc a strong growth stockAnalyst Upgrade & AI Powered Market Trend Analysis - baoquankhu1.vn
Bear Alert: Will Denali Therapeutics Inc benefit from government policy2025 Market Overview & Fast Entry High Yield Stock Tips - baoquankhu1.vn
DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies - TradingView — Track All Markets
Denali Therapeutics unveils portfolio goals for 2026, stock up - MSN
Market Outlook: Is Denali Therapeutics Inc a turnaround storyStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential - DirectorsTalk Interviews
Rate Hike: Can Denali Therapeutics Inc scale operations efficientlyQuarterly Investment Review & Stepwise Trade Signal Implementation - baoquankhu1.vn
Have Denali Therapeutics Insiders Been Selling Stock? - simplywall.st
Why (DNLI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Is Denali Therapeutics Inc. stock a good choice for value investors2025 Technical Patterns & Daily Volume Surge Trade Alerts - ulpravda.ru
What insider trading reveals about Denali Therapeutics Inc. stockRecession Risk & AI Powered Market Trend Analysis - Улправда
Investment Recap: Is Denali Therapeutics Inc stock recession proof2025 Top Gainers & Precise Buy Zone Identification - moha.gov.vn
DNLI Stock Price, Forecast & Analysis | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - Chartmill
Why analysts upgrade Denali Therapeutics Inc. stockQuarterly Trade Report & Low Drawdown Momentum Trade Ideas - Улправда
What RSI levels show for Denali Therapeutics Inc. (4DN) stockJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - Улправда
Ryan Watts Sells 35,198 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Sells Shares - TradingView — Track All Markets
Is Denali Therapeutics Inc. stock recession proofJuly 2025 Final Week & AI Powered Buy and Sell Recommendations - Улправда
Will Denali Therapeutics Inc. stock reach all time highs in 2025Quarterly Market Summary & Long-Term Growth Plans - Улправда
What risks investors should watch in Denali Therapeutics Inc. stockStochastic Oscillator Alerts & Outstanding Profit Investment - Улправда
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance
The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance
Performance Recap: Will Denali Therapeutics Inc. stock reach all time highs in 20252025 EndofYear Setup & Risk Managed Investment Entry Signals - Bộ Nội Vụ
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - sharewise.com
Will Denali Therapeutics Inc. stock see insider buyingMarket Depth Overview & Unlock Patterns Humans Can’t See - Улправда
Denali Therapeutics outlines key milestones for 2026 By Investing.com - Investing.com Nigeria
Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential - Investing.com South Africa
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flows2026 world cup usa national team round of 32 young talents transition play winner prediction expert opinion - ulpravda.ru
Denali Prepares For Key Clinical And Regulatory Milestones - Nasdaq
Denali Therapeutics announces key anticipated milestones and priorities for 2026 - MarketScreener
Denali Therapeutics outlines key milestones for 2026 - Investing.com
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision - TipRanks
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome - The Manila Times
Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets
Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.06%
大文字化:
|
ボリューム (24 時間):